Ahmet Tezel, Chief Innovation Officer of LivaNova PLC (NASDAQ:LIVN), filed a Form 4 on August 13, 2026, reporting multiple transactions in the company's ordinary shares on August 11, 2026.

Key Highlights

  • Transaction date: All reported transactions occurred on August 11, 2026.
  • SAR exercise: Tezel exercised stock appreciation rights covering 12,692 ordinary shares at a base price of $52.68, acquiring 12,692 shares via transaction code M.
  • Shares withheld for base price: 8,589 shares were withheld at $77.86 in connection with the SAR exercise (transaction code D).
  • Shares withheld for taxes: 1,428 shares were withheld at $77.86 to satisfy tax liability (transaction code F).
  • Open-market sale: 2,675 shares were sold at a weighted-average price of $77.7355, with individual transaction prices ranging from $77.6684 to $77.7900.
  • Remaining beneficial ownership: Following all transactions, Tezel directly held 6,090 ordinary shares, with 12,691 stock appreciation rights still outstanding.

Details of Tezel's August 11 Transactions in LivaNova Ordinary Shares

According to the filing, Ahmet Tezel, who serves as Chief Innovation Officer of LivaNova PLC, a medical device company listed on NASDAQ, exercised stock appreciation rights on August 11, 2026. The SARs, originally granted on June 15, 2024, vest in four equal annual installments beginning June 15, 2025, and are governed by the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and the applicable award agreement, according to the filing.

The filing reports that the exercise of 12,692 SARs at a base price of $52.68 per share resulted in an acquisition of 12,692 ordinary shares. Following that acquisition, 8,589 shares were withheld at $77.86 as payment of the base price, and 1,428 additional shares were withheld at $77.86 to satisfy tax obligations. Separately, 2,675 shares were sold in multiple open-market transactions at prices ranging from $77.6684 to $77.7900, with the filing reporting a weighted-average sale price of $77.7355. The filing notes that full information on the number of shares sold at each separate price is available upon request.

After all four reported transactions, Tezel's direct beneficial ownership stood at 6,090 ordinary shares, with 12,691 stock appreciation rights remaining, according to the disclosure. The form was signed by Sarah K. Mohr as Attorney-in-Fact on August 13, 2026.

What Was Disclosed

The filing reported a SAR exercise, two share-withholding events covering base price and tax obligations, and one open-market sale of ordinary shares by LivaNova's Chief Innovation Officer, all occurring on August 11, 2026, resulting in direct beneficial ownership of 6,090 shares.